January 2022

A presentation at the 63rd American Society of Hematology (ASH) annual meeting explored the collection of real-world data.

The 63rd American Society of Hematology (ASH) Annual Meeting and Exposition featured leading experts who discussed research on multiple myeloma.

Ongoing and new developments in chimeric antigen receptor (CAR) T-cell therapies were covered at the 63rd American Society of Hematology (ASH) annual meeting.

Clinical trial results in the leukemia and lymphoma space were covered at the 63rd American Society of Hematology (ASH) annual meeting.

Disparities and inequities in care were topics of interest at the 63rd American Society of Hematology (ASH) annual meeting.

Featuring abstracts from the Association of Community Cancer Centers, US Oncology, City of Hope, and Florida Cancer Specialists & Research Institute.